Eli Lilly and Company Company Profile (NYSE:LLY)

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and Company announced a quarterly dividend on Monday, June 19th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 annualized dividend and a dividend yield of 2.54%. The ex-dividend date is Friday, August 11th. View Eli Lilly and Company's Dividend History.

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings data on Tuesday, July, 25th. The company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.06. The firm earned $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and Company had a return on equity of 28.71% and a net margin of 11.12%. The company's revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 earnings per share. View Eli Lilly and Company's Earnings History.

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Eli Lilly and Company.

Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $22.0-22.5 billion, compared to the consensus revenue estimate of $22.15 billion.

18 brokerages have issued twelve-month price targets for Eli Lilly and Company's stock. Their forecasts range from $71.00 to $105.00. On average, they expect Eli Lilly and Company's share price to reach $89.18 in the next year. View Analyst Ratings for Eli Lilly and Company.

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

• 1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
• 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
• 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Some companies that are related to Eli Lilly and Company include Novo Nordisk A/S (NVO), Sanofi (SNY), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Catalent (CTLT), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Akorn (AKRX) and Opko Health (OPK).

Eli Lilly and Company's management team includes the folowing people:

• David A. Ricks, Chairman of the Board, President, Chief Executive Officer
• Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
• Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
• Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
• Michael J. Harrington, Senior Vice President, General Counsel
• Stephen F. Fry, Senior Vice President - Human Resources and Diversity
• Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
• Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
• Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
• Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Eli Lilly and Company's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Lilly Endowment Inc. (11.76%), Vanguard Group Inc. (6.65%), BlackRock Inc. (6.03%), State Street Corp (3.98%), Franklin Resources Inc. (2.66%) and State Farm Mutual Automobile Insurance Co. (1.89%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Winslow Capital Management LLC, Franklin Resources Inc., Bank of New York Mellon Corp, FMR LLC, American Century Companies Inc., UBS Asset Management Americas Inc. and Capital Guardian Trust Co.. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Eli Lilly and Company's stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Dodge & Cox, Renaissance Technologies LLC, Harbour Capital Advisors LLC, Vanguard Group Inc., AJO LP, Westfield Capital Management Co. LP and BlackRock Inc.. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Eli Lilly and Company stock can currently be purchased for approximately $82.02.